View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 14, 2011

Arena Shows Efficacy Against Pulmonary Hypertension

Arena Pharmaceuticals has announced results from a Phase I clinical trial of an orally bioavailable agonist of the prostacyclin receptor, APD811, as a treatment for pulmonary arterial hypertension. The randomised, double-blind and placebo-controlled trial enrolled 32 healthy volunteers

By cms admin

Arena Pharmaceuticals has announced results from a Phase I clinical trial of an orally bioavailable agonist of the prostacyclin receptor, APD811, as a treatment for pulmonary arterial hypertension.

The randomised, double-blind and placebo-controlled trial enrolled 32 healthy volunteers in four cohorts of eight participants each. The drug showed dose-proportional pharmacokinetic exposure over the tested dose range.

Arena senior vice-president and chief medical officer William Shanahan said that the encouraging results of the study will make the company further evaluate the safety, tolerability and pharmacokinetics of multiple dosing and the optimal titration schedule in a Phase Ib trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology